Upfront pembrolizumab as an effective treatment start in patients with PD-L1 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis

CONCLUSIONS: Upfront pembrolizumab showed efficacy in selected patients with PD-L1 ≥ 50% non-oncogene addicted NSCLC and asymptomatic BMs. Prospective studies should address whether pembrolizumab alone, and deferral of radiotherapy, could be pursued in this patient population.PMID:33728869 | DOI:10.1007/s12094-021-02588-8

Source: Clinical Lung Cancer - March 17, 2021 Category: Cancer & Oncology Authors: G Metro A Gili D Signorelli A De Toma M Garaffa D Galetta P Economopoulou A Friedlaender B Jimenez A Collazo-Lorduy A Addeo P Chiarini C Costa G Mountzios F Roila Source Type: research